Overview

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Status:
RECRUITING

Trial end date:
2028-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. 2. Determine how well the combination treatment of olutasidenib, venetoclax, and azacitidine works compared to the usual chemotherapy treatment that people with this condition receive.

Phase:

PHASE2

Details

Lead Sponsor:

Justin Watts, MD

Collaborator:

Rigel Pharmaceuticals

Treatments:

Azacitidine
olutasidenib
venetoclax